OmniAb Beheer

Beheer criteriumcontroles 3/4

Momenteel beschikken wij niet over voldoende informatie over de CEO.

Belangrijke informatie

Matt Foehr

Algemeen directeur

US$2.6m

Totale compensatie

Percentage CEO-salaris	21.3%
Dienstverband CEO	2yrs
Eigendom CEO	3.0%
Management gemiddelde ambtstermijn	2yrs
Gemiddelde ambtstermijn bestuur	2yrs

Recente managementupdates

Recent updates

OmniAb, Inc. (NASDAQ:OABI) Just Reported And Analysts Have Been Cutting Their Estimates

Nov 15

Is OmniAb (NASDAQ:OABI) In A Good Position To Invest In Growth?

Sep 14

Are Investors Undervaluing OmniAb, Inc. (NASDAQ:OABI) By 43%?

Jul 15

The OmniAb, Inc. (NASDAQ:OABI) First-Quarter Results Are Out And Analysts Have Published New Forecasts

May 12

Things Look Grim For OmniAb, Inc. (NASDAQ:OABI) After Today's Downgrade

Mar 26

Revenues Not Telling The Story For OmniAb, Inc. (NASDAQ:OABI)

Feb 28

OmniAb, Inc.'s (NASDAQ:OABI) Intrinsic Value Is Potentially 37% Above Its Share Price

Jan 15

Unpleasant Surprises Could Be In Store For OmniAb, Inc.'s (NASDAQ:OABI) Shares

Nov 11

Earnings Update: OmniAb, Inc. (NASDAQ:OABI) Just Reported And Analysts Are Trimming Their Forecasts

Aug 13

OmniAb, Inc. (NASDAQ:OABI) Analysts Just Cut Their EPS Forecasts Substantially

May 14

Analyse CEO-vergoeding

Hoe is Matt Foehr's beloning veranderd ten opzichte van OmniAb's winst?
Datum	Totale vergoeding	Salaris	Bedrijfswinsten
Sep 30 2024	n/a	n/a	-US$63m
Jun 30 2024	n/a	n/a	-US$62m
Mar 31 2024	n/a	n/a	-US$63m
Dec 31 2023	US$3m	US$564k	-US$51m
Sep 30 2023	n/a	n/a	-US$30m
Jun 30 2023	n/a	n/a	-US$27m
Mar 31 2023	n/a	n/a	-US$22m
Dec 31 2022	US$7m	US$542k	-US$22m
Sep 30 2022	n/a	n/a	-US$32m
Jun 30 2022	n/a	n/a	-US$28m
Mar 31 2022	n/a	n/a	-US$25m
Dec 31 2021	US$5m	US$519k	-US$27m
Sep 30 2021	n/a	n/a	-US$24m
Dec 31 2020	US$3m	US$504k	-US$18m

Compensatie versus markt: De totale vergoeding ($USD 2.65M ) Matt } is ongeveer het gemiddelde voor bedrijven van vergelijkbare omvang in de US markt ($USD 2.14M ).

Compensatie versus inkomsten: De vergoeding van Matt is het afgelopen jaar in lijn geweest met de bedrijfsprestaties.

CEO

Matt Foehr (51 yo)

2yrs

Tenure

US$2,647,424

Compensatie

Mr. Matthew W. Foehr, also known as Matt, has been the President, Chief Executive Officer and Director of OmniAb, Inc. since November 1, 2022. Mr. Foehr has been the Chief Executive Officer and President a...

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
Matthew Foehr	President	2yrs	US$2.65m	2.97% $ 14.1m
Kurt Gustafson	Executive VP of Finance & CFO	2yrs	US$1.29m	0.15% $ 692.7k
Charles Berkman	Chief Legal Officer & Secretary	2yrs	US$1.34m	0.24% $ 1.1m
Cia McCaffrey	Vice President of People & Talent	1.8yrs	geen gegevens	geen gegevens
Bill Harriman	Senior Vice President of Antibody Discovery	no data	geen gegevens	geen gegevens
Marie-Cecile van de Lavoir	Senior Vice President of Technical Operations & Genetics	no data	geen gegevens	geen gegevens
Christel Iffland	Senior Vice President of Antibody Technologies	no data	geen gegevens	geen gegevens
Douglas Krafte	Senior VP of Ion Channels/Transporters & Icagen Ion Channel Technology Site Head	no data	geen gegevens	geen gegevens
Donna Ventura	Senior VP & Corporate Controller	2.4yrs	geen gegevens	geen gegevens

2.0yrs

Gemiddelde duur

55.5yo

Gemiddelde leeftijd

Ervaren management: Het managementteam van OABI wordt beschouwd als ervaren (gemiddelde ambtstermijn 2 jaar).

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Matthew Foehr	President	2yrs	US$2.65m	2.97% $ 14.1m
John Higgins	Chairman	2yrs	US$774.95k	1.66% $ 7.9m
Carolyn Bertozzi	Independent Director	2yrs	US$447.25k	0.046% $ 217.7k
Steven Love	Independent Director	less than a year	US$371.54k	0.011% $ 52.3k
Sarah Boyce	Independent Director	2yrs	US$356.55k	0.072% $ 343.7k
Jennifer Cochran	Independent Director	2yrs	US$493.56k	0.086% $ 408.5k

2.0yrs

Gemiddelde duur

53yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van OABI wordt niet als ervaren beschouwd (gemiddelde ambtstermijn 2 jaar), wat duidt op een nieuw bestuur.

OmniAb Beheer

Beheer criteriumcontroles 3/4

Belangrijke informatie

Recente managementupdates

OmniAb, Inc., Annual General Meeting, Jun 18, 2024

President exercised options and sold US$98k worth of stock

President exercised options to buy US$1.3m worth of stock.

President recently bought US$1.2m worth of stock

President exercised options and sold US$105k worth of stock

President recently bought US$1.0m worth of stock

Recent updates

OmniAb, Inc. (NASDAQ:OABI) Just Reported And Analysts Have Been Cutting Their Estimates

OmniAb, Inc. to Report Q3, 2024 Results on Nov 12, 2024

Is OmniAb (NASDAQ:OABI) In A Good Position To Invest In Growth?

OmniAb, Inc. to Report Q2, 2024 Results on Aug 08, 2024

Are Investors Undervaluing OmniAb, Inc. (NASDAQ:OABI) By 43%?

The OmniAb, Inc. (NASDAQ:OABI) First-Quarter Results Are Out And Analysts Have Published New Forecasts

First quarter 2024 earnings: EPS and revenues miss analyst expectations

Now 20% undervalued after recent price drop

OmniAb, Inc., Annual General Meeting, Jun 18, 2024

OmniAb, Inc. to Report Q1, 2024 Results on May 09, 2024

Now 21% undervalued after recent price drop

President exercised options and sold US$98k worth of stock

President exercised options to buy US$1.3m worth of stock.

President recently bought US$1.2m worth of stock

Things Look Grim For OmniAb, Inc. (NASDAQ:OABI) After Today's Downgrade

Consensus revenue estimates fall by 31%

No longer forecast to breakeven

Revenues Not Telling The Story For OmniAb, Inc. (NASDAQ:OABI)

OmniAb, Inc. to Report Q4, 2023 Results on Mar 20, 2024

President exercised options and sold US$105k worth of stock

OmniAb, Inc.'s (NASDAQ:OABI) Intrinsic Value Is Potentially 37% Above Its Share Price

Forecast to breakeven in 2026

OmniAb, Inc. Presents New Scientific Data on its OmnidAb Platform at the 2023 Antibody Engineering & Therapeutics Conference

President recently bought US$1.0m worth of stock

Executive VP of Finance & CFO exercised options and sold US$78k worth of stock

Consensus revenue estimates fall by 22%

President recently bought US$406k worth of stock

Unpleasant Surprises Could Be In Store For OmniAb, Inc.'s (NASDAQ:OABI) Shares

Third quarter 2023 earnings: EPS and revenues miss analyst expectations

Omniab, Inc. Appoints Steve Love to Its Board of Directors and as Audit Committee Chair, Member of the Human Capital Management and Compensation Committee

OmniAb, Inc. Appoints Steve Love to its Board of Directors and as Audit Committee Chair

OmniAb, Inc. to Report Q3, 2023 Results on Nov 09, 2023

Now 20% undervalued

President recently bought US$247k worth of stock

Consensus revenue estimates fall by 14%

Earnings Update: OmniAb, Inc. (NASDAQ:OABI) Just Reported And Analysts Are Trimming Their Forecasts

Now 22% undervalued

Omniab Announces the Passing of Director Sunil Patel

OmniAb, Inc. to Report Q2, 2023 Results on Aug 10, 2023

President recently bought US$520k worth of stock

Chairman notifies of intention to sell stock

Consensus revenue estimates fall by 10%

President recently bought US$1.5m worth of stock

OmniAb, Inc. (NASDAQ:OABI) Analysts Just Cut Their EPS Forecasts Substantially

First quarter 2023 earnings: EPS and revenues miss analyst expectations

Full year 2022 earnings: EPS and revenues exceed analyst expectations

President recently bought US$565k worth of stock

Independent Director recently bought US$84k worth of stock

President recently bought US$1.0m worth of stock

No independent directors

President recently bought US$276k worth of stock

Chairman exercised options to buy US$533k worth of stock.

OmniAb, Inc. completed the acquisition of Avista Public Acquisition Corp. II (NasdaqCM:AHPA) (APAC) from Avista Capital Holdings, L.P., Polar Asset Management Partners Inc., Citadel Advisors LLC, HGC Investment Management Inc., Beryl Capital Management LLC and others.

OmniAb, Inc. Appoint Board of Directors

No independent directors

Analyse CEO-vergoeding

CEO

Tenure

Compensatie

Leiderschapsteam

Gemiddelde duur

Gemiddelde leeftijd

Bestuursleden

Gemiddelde duur

Gemiddelde leeftijd